
Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC
The addition of darolutamide (Nubeqa) to androgen deprivation therapy (ADT) significantly delayed radiological progression, elicited deep and durable prostate-specific antigen (PSA) responses, and prolonged time to pain progression in patients with …